NASDAQ: ASNDAscendis Pharma A Stock
$157.60+0.06 (+0.04%)
Updated May 16, 2025
ASND Price
$157.60
Fair Value Price
N/A
Market Cap
$9.56B
52 Week Low
$111.09
52 Week High
$183.00
P/E
-23.71x
P/B
-44.34x
P/S
23.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$418.98M
Earnings
-$371.38M
Gross Margin
85.3%
Operating Margin
-51.29%
Profit Margin
-92.7%
Debt to Equity
-6.59
Operating Cash Flow
-$238M
Beta
0.69
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ASND Overview
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ASND's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ASND
Ranked#136 of 456
Ranked#136 of 456
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $46.01 | A | |
| $8.19 | A | |
| $63.31 | A |
Be the first to know about important ASND news, forecast changes, insider trades & much more!
ASND News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ASND scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ASND is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ASND is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ASND's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ASND due diligence checks available for Premium users.
Valuation
ASND price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-23.71x
Industry
-154.88x
Market
25.95x
ASND price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-44.34x
Industry
4.21x
ASND's financial health
Profit margin
Revenue
$109.7M
Net Income
-$102.9M
Profit Margin
-93.7%
ASND's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ASND's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$1.4B
Debt to equity
-6.59
ASND's short-term assets ($1.05B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASND's short-term assets ($1.05B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASND's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ASND's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.6M
Investing
-$764.1k
Financing
-$19.6M
ASND's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ASND vs Biotech Stocks
Ascendis Pharma A Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.